SG155186A1 - Il-17 antagonistic antibodies - Google Patents

Il-17 antagonistic antibodies

Info

Publication number
SG155186A1
SG155186A1 SG200905203-6A SG2009052036A SG155186A1 SG 155186 A1 SG155186 A1 SG 155186A1 SG 2009052036 A SG2009052036 A SG 2009052036A SG 155186 A1 SG155186 A1 SG 155186A1
Authority
SG
Singapore
Prior art keywords
antagonistic antibodies
antibody
human
disorder
heavy
Prior art date
Application number
SG200905203-6A
Other languages
English (en)
Inventor
Padova Franco E Di
Hermann Gram
Hans Hofstetter
Margit Jeschke
Jean-Michel Rondeau
Den Berg Wim Van
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG155186(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG155186A1 publication Critical patent/SG155186A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG200905203-6A 2004-08-05 2005-08-04 Il-17 antagonistic antibodies SG155186A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417487.6A GB0417487D0 (en) 2004-08-05 2004-08-05 Organic compound

Publications (1)

Publication Number Publication Date
SG155186A1 true SG155186A1 (en) 2009-09-30

Family

ID=32982602

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200905203-6A SG155186A1 (en) 2004-08-05 2005-08-04 Il-17 antagonistic antibodies

Country Status (40)

Country Link
US (9) US7807155B2 (en:Method)
EP (5) EP2366405B1 (en:Method)
JP (1) JP4682200B2 (en:Method)
KR (2) KR20080029018A (en:Method)
CN (1) CN101001645B (en:Method)
AR (1) AR050200A1 (en:Method)
AT (1) ATE517924T1 (en:Method)
AU (2) AU2005268857C1 (en:Method)
BE (1) BE2015C041I2 (en:Method)
BR (3) BR122017009404B1 (en:Method)
CA (1) CA2573586C (en:Method)
CY (6) CY1111963T1 (en:Method)
DK (4) DK2902039T3 (en:Method)
EC (1) ECSP077198A (en:Method)
ES (4) ES2487533T7 (en:Method)
FR (1) FR15C0048I2 (en:Method)
GB (1) GB0417487D0 (en:Method)
HK (1) HK1256639A1 (en:Method)
HR (3) HRP20110758T4 (en:Method)
HU (4) HUE025815T2 (en:Method)
IL (1) IL180717A (en:Method)
LT (3) LT2902039T (en:Method)
LU (2) LU92768I2 (en:Method)
MA (1) MA28982B1 (en:Method)
MX (1) MX2007001338A (en:Method)
MY (1) MY144925A (en:Method)
NL (1) NL300749I2 (en:Method)
NO (9) NO336279B1 (en:Method)
NZ (1) NZ552658A (en:Method)
PE (1) PE20060418A1 (en:Method)
PL (4) PL2366405T3 (en:Method)
PT (4) PT2364729E (en:Method)
RU (2) RU2426741C3 (en:Method)
SG (1) SG155186A1 (en:Method)
SI (4) SI2902039T1 (en:Method)
TN (1) TNSN07034A1 (en:Method)
TR (1) TR201808057T4 (en:Method)
TW (1) TWI359153B (en:Method)
WO (1) WO2006013107A1 (en:Method)
ZA (1) ZA200700242B (en:Method)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
AU2006284841B2 (en) * 2005-09-01 2012-11-08 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
EP3808769A1 (en) * 2005-12-13 2021-04-21 Eli Lilly And Company Anti-il-17 antibodies
UA97946C2 (ru) 2005-12-20 2012-04-10 Эс-Би-Ай Биотех Ко., Лтд. Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
RU2430110C2 (ru) * 2006-01-31 2011-09-27 Новартис Аг Антитела - антагонисты интерлейкина-17 (ил-17) для лечения рака
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
TW200815469A (en) 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
CN101646690B (zh) 2006-08-11 2013-10-23 默沙东公司 抗il-17a抗体
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
AU2008219681A1 (en) 2007-02-28 2008-09-04 Merck Sharp & Dohme Corp. Combination therapy for treatment of immune disorders
EP4177268A3 (en) 2007-05-29 2023-05-24 Novartis AG New indications for anti-il-1beta therapy
WO2008156865A2 (en) * 2007-06-20 2008-12-24 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
ES2614735T3 (es) * 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
WO2009033091A1 (en) * 2007-09-06 2009-03-12 City Of Hope Treatment of th17-mediated autoimmune disease via inhibition of stat3
WO2009072802A2 (en) * 2007-12-03 2009-06-11 Amorepacific Corporation Composition for slimming
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
JP5886523B2 (ja) 2008-01-09 2016-03-16 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の炎症性障害を処置するための治療組成物
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2717987C (en) * 2008-04-29 2018-11-13 Micromet Ag Inhibitors of gm-csf and il-17 for therapy
KR20150002874A (ko) 2008-05-05 2015-01-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
KR20110016958A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
RU2539029C2 (ru) * 2008-09-29 2015-01-10 Роше Гликарт Аг Антитела против интерлейкина 17 (ил-17) человека и их применение
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
CN104725512A (zh) * 2009-04-27 2015-06-24 诺华股份有限公司 增加肌肉生长的组合物和方法
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
AU2010289527C1 (en) 2009-09-01 2014-10-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN102648002A (zh) * 2009-10-10 2012-08-22 斯坦福大学托管董事会 Il-17家族细胞因子组合物及用途
WO2011047262A2 (en) 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
AU2010313304B2 (en) 2009-10-30 2015-08-20 Janssen Biotech, Inc. IL-17A antagonists
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
SG188190A1 (en) 2010-08-03 2013-04-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2012018767A2 (en) 2010-08-05 2012-02-09 Anaptysbio, Inc. Antibodies directed against il-17
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
KR20130139884A (ko) 2010-08-26 2013-12-23 애브비 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
LT3590949T (lt) 2010-10-01 2022-07-25 Modernatx, Inc. Ribonukleorūgštys, kurių sudėtyje yra n1-metil-pseudouracilų, ir jų naudojimas
MX356279B (es) * 2010-10-08 2018-05-22 Novartis Ag Star Métodos para el tratamiento de soriasis usando antagonistas de il-17.
MX362591B (es) 2010-11-05 2019-01-25 Novartis Ag Uso de antagonistas de il-17.
AU2014259526B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating ankylosing spondylitis using IL-17 antagonists
WO2012082573A1 (en) 2010-12-13 2012-06-21 Novartis Ag Predictive methods and methods of treating arthritis using il-17 antagonists
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なｉｌ−１７産生抑制剤
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
EP2663869A1 (en) * 2011-01-13 2013-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for predicting the risk of having a cardiovascular event in a subject
ES2632583T3 (es) 2011-01-14 2017-09-14 Ucb Biopharma Sprl Anticuerpo que se une a IL-17A e IL-17F
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
WO2012135415A1 (en) * 2011-03-29 2012-10-04 Glaxosmithkline Llc Buffer system for protein purification
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SMT202200229T1 (it) 2011-10-03 2022-07-21 Modernatx Inc Nucleosidi, nucleotidi e acidi nucleici modificati e loro usi
EP2783014A1 (en) 2011-11-21 2014-10-01 Novartis AG Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non- response alleles
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
WO2013087913A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
MX2014007233A (es) 2011-12-16 2015-02-04 Moderna Therapeutics Inc Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
MX2014008101A (es) 2011-12-30 2014-09-25 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17.
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
DE18200782T1 (de) 2012-04-02 2021-10-21 Modernatx, Inc. Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen
EP2834273B1 (en) 2012-04-05 2018-08-22 F.Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
CA2870025A1 (en) 2012-04-20 2013-10-24 Novartis Ag Methods of treating ankylosing spondylitis using il-17 antagonists
JP6362587B2 (ja) 2012-05-22 2018-07-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｌ−１７ａ／ｆｉｌ−２３二重特異性抗体およびその使用
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
SG11201503412RA (en) 2012-11-01 2015-05-28 Abbvie Inc Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
CA3185317A1 (en) 2013-02-08 2014-08-14 Novartis Ag Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
CN105324396A (zh) 2013-03-15 2016-02-10 艾伯维公司 针对IL-1β和/或IL-17的双重特异性结合蛋白
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
EP3033107A1 (en) * 2013-08-15 2016-06-22 Novartis AG Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
EP3889178A1 (en) 2013-08-30 2021-10-06 Takeda GmbH Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
EP3670533A1 (en) * 2013-11-18 2020-06-24 Shanghai Hengrui Pharmaceutical Co. Ltd. Il-17a binding agent and uses thereof
JP2017508446A (ja) * 2014-01-28 2017-03-30 北京韓美薬品有限公司 二機能性融合タンパク質及びその製造方法並びに使用
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
FI3191120T3 (fi) 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
RU2609627C2 (ru) 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
ES2952717T3 (es) 2014-10-14 2023-11-03 Novartis Ag Moléculas de anticuerpos contra PD-L1 y usos de las mismas
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
HUE052121T2 (hu) 2015-01-12 2021-04-28 Affibody Ab Il-17A-hoz kötõdõ polipeptidek
EP3250927B1 (en) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Gene expression markers and treatment of multiple sclerosis
CN108251431B (zh) * 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP2018521047A (ja) 2015-07-16 2018-08-02 イーライ リリー アンド カンパニー 掻痒の治療
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
JP6878405B2 (ja) 2015-07-29 2021-05-26 ノバルティス アーゲー Ｐｄ−１に対する抗体分子を含む組み合わせ治療
IL297775A (en) 2015-10-19 2022-12-01 Novartis Ag Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
PT3426680T (pt) 2016-03-10 2024-10-02 Acceleron Pharma Inc Proteínas de ligação ao recetor de activina de tipo 2 e as suas utilizações
US11072652B2 (en) 2016-03-10 2021-07-27 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
RU2680011C2 (ru) 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
FR3051673B1 (fr) * 2016-05-24 2018-06-22 Assistance Publique - Hopitaux De Paris Inhibiteurs de la voie de l'interleukine 17 pour le traitement des infections chroniques dues a hpv
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业（上海）股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
CN109476733A (zh) 2016-07-19 2019-03-15 诺华股份有限公司 使用il-17拮抗剂治疗新发斑块型银屑病的方法
ES2905917T3 (es) 2016-09-14 2022-04-12 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo que se une específicamente a IL-17A y fragmento funcional del mismo
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法
BR112019016595A2 (pt) 2017-02-10 2020-03-31 Genentech, Inc. Anticorpos isolados, métodos de produção do anticorpo e de tratamento de um distúrbio, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, composições farmacêuticas e uso
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 使用il-17拮抗劑選擇性治療氣喘的方法
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术（上海）有限公司 靶向于白介素17a的抗体、其制备方法和应用
US20210179702A1 (en) 2017-11-02 2021-06-17 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
US20200277369A1 (en) * 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
EP3717907A1 (en) 2017-11-30 2020-10-07 Novartis AG Bcma-targeting chimeric antigen receptor, and uses thereof
CN112203685A (zh) * 2018-03-29 2021-01-08 瑞美德生物医药科技有限公司 使用结合白细胞介素-17a(il-17a)的抗体的自身免疫紊乱和炎性紊乱的治疗
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
WO2020064702A1 (en) 2018-09-25 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
SG11202107995SA (en) 2019-01-31 2021-08-30 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
CN110179746A (zh) 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
US11878037B2 (en) 2019-05-31 2024-01-23 Figene, Llc Concurrent activation of regenerative and tolerogenic processes by fibroblast-based compositions for the treatment of multiple sclerosis
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
JP7214921B2 (ja) 2019-07-26 2023-01-30 神州細胞工程有限公司 ヒト化抗ｉｌ１７ａ抗体及びその使用
CN114127108A (zh) 2019-07-30 2022-03-01 江苏恒瑞医药股份有限公司 Il-17拮抗剂治疗自身免疫疾病的方法
AU2020347952A1 (en) 2019-09-20 2022-04-07 Novartis Ag Methods of treating autoimmune diseases using interleukin-17 (IL-17) antagonists
TWI870471B (zh) * 2019-09-25 2025-01-21 國立大學法人東京大學 全身性硬化症治療用醫藥組合物
EP4042167B1 (en) 2019-09-30 2025-04-09 Janssen Pharmaceutica NV Compositions and methods for an il-17 target engagement assay with large molecule modulators
WO2021099924A1 (en) 2019-11-19 2021-05-27 Novartis Ag Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists
AU2020396455A1 (en) 2019-12-06 2022-06-02 Novartis Ag Methods of treating lichen planus using Interleukin-17 (IL-17) antagonists
CN114805577B (zh) * 2019-12-31 2023-11-21 南京融捷康生物科技有限公司 针对il-17ra蛋白的抗体及其制备方法和应用
CN115812079A (zh) 2020-06-23 2023-03-17 诺华股份有限公司 使用白细胞介素-17(il-17)拮抗剂治疗甲状腺眼病和格雷夫斯眼眶病的方法
UY39484A (es) 2020-11-02 2022-06-30 Novartis Ag Inhibidores de interleucina-17
KR20230104651A (ko) 2020-11-06 2023-07-10 노파르티스 아게 Cd19 결합 분자 및 이의 용도
US20240043523A1 (en) 2020-12-02 2024-02-08 Fresenius Kabi Deutschland Gmbh Methods of selectively reducing antibodies
CN116635416A (zh) 2020-12-22 2023-08-22 诺华股份有限公司 用于在细胞培养期间降低分泌的重组表达蛋白质中半胱氨酸残基的氧化水平的方法
CN119137115A (zh) 2022-04-25 2024-12-13 诺华股份有限公司 Il-17抑制剂的晶型
WO2023223211A1 (en) 2022-05-16 2023-11-23 Novartis Ag Methods of treating giant cell arteritis using interleukin-17 (il-17) antagonists
JP2025516723A (ja) 2022-05-18 2025-05-30 ノバルティス アーゲー インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を選択的に治療する方法
WO2024156841A1 (en) * 2023-01-27 2024-08-02 Fresenius Kabi Deutschland Gmbh Biopharmaceutical composition
EP4406553A1 (en) * 2023-01-27 2024-07-31 Fresenius Kabi Deutschland GmbH Stable secukinumab biopharmaceutical composition
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
CN117843778B (zh) * 2023-12-21 2024-07-26 北京贝来药业有限公司 针对白介素家族成员的新型纳米抗体及其产品和应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN119331085B (zh) * 2024-10-16 2025-03-14 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
ES2229264T5 (es) 1995-03-23 2009-12-17 Immunex Corporation Receptor il-17.
CA2227220A1 (en) * 1995-07-19 1997-02-06 Genetics Institute, Inc. Human ctla-8 and uses of ctla-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
DK0862454T3 (da) 1995-10-27 2002-12-30 Schering Corp CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
DE69739375D1 (de) 1996-11-27 2009-06-04 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid-erzeugung
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
CA2309604C (en) 1997-11-10 2010-01-12 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
AU2031399A (en) 1998-01-09 1999-07-26 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
CA2317817A1 (en) 1998-01-09 1999-07-15 Immunex Corporation Il-17rh dna and polypeptides
MXPA00007889A (es) 1998-02-11 2002-09-18 Maxygen Inc Optimizacion de las propiedades inmunomoduladoras de las vacunas geneticas.
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
ATE378408T1 (de) 1998-09-17 2007-11-15 Zymogenetics Inc Transformierender wachstumsfaktor beta-9 (ztgfss9) aus säugetieren
AU6277799A (en) 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Snow Brand Milk Prod Co Ltd 慢性関節リウマチ治療剤及び診断方法
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter, Werner, Prof. Dr.med., 14195 Berlin Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
AU3207000A (en) 1999-01-11 2000-08-01 Schering Corporation Interleukin-17 related mammalian cytokine (il-171). polynucleotides encoding them. uses
SI1141297T1 (sl) 1999-01-11 2010-01-29 Schering Corp Interlevkinu-17 sorodni sesalski citokini, polinukleotidi, ki jih kodirajo uporabe
SI1031346T1 (en) 1999-01-27 2002-08-31 Idea Ag Noninvasive vaccination through the skin
DK1156823T3 (da) 1999-02-12 2009-01-19 Scripps Research Inst Fremgangsmåder til behandling af tumorer og metastaser ved anvendelse af en kombination af anti-angiogene terapier og immunoterapier
EP1053751A1 (en) * 1999-05-17 2000-11-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Compositions and methods for treating cell proliferation disorders
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
WO2001015728A1 (en) 1999-08-27 2001-03-08 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
ATE494304T1 (de) 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP1326974B1 (en) 2000-10-13 2006-12-27 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
EP1326626B1 (en) * 2000-10-18 2020-04-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
ATE501730T1 (de) 2001-01-25 2011-04-15 Zymogenetics Inc Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
CA2467521A1 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
MXPA05012571A (es) * 2003-05-21 2006-02-08 Medarex Inc Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
EP2974742A1 (en) 2003-11-21 2016-01-20 UCB Biopharma SPRL Method for the treatment of multiple sclerosis by inhibiting il-17 activity
MXPA06012754A (es) * 2004-05-03 2007-02-19 Schering Corp El uso de la expresion de il-17 para predecir la inflamacion de la piel: metodos de tratamiento.
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
AU2006284841B2 (en) 2005-09-01 2012-11-08 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease

Also Published As

Publication number Publication date
US20250122277A1 (en) 2025-04-17
CY1120723T1 (el) 2019-12-11
ES2367440T3 (es) 2011-11-03
NO337129B1 (no) 2016-01-25
CY2018027I2 (el) 2020-05-29
ES2487533T7 (es) 2015-07-14
DK2364729T3 (da) 2014-07-21
NO2016017I1 (no) 2016-08-23
PL1776142T6 (pl) 2016-06-30
EP1776142A1 (en) 2007-04-25
EP1776142B9 (en) 2016-09-07
CA2573586A1 (en) 2006-02-09
ES2367440T7 (es) 2015-07-14
TW200617025A (en) 2006-06-01
EP2364729B3 (en) 2015-06-24
DK2364729T6 (en) 2015-07-06
US20230235038A1 (en) 2023-07-27
HRP20150480T1 (hr) 2015-07-17
KR20080029018A (ko) 2008-04-02
TR201808057T4 (tr) 2018-06-21
FR15C0048I1 (fr) 2015-08-28
EP2902039B1 (en) 2018-04-11
NO2018007I1 (no) 2018-02-14
LUC00088I2 (en:Method) 2018-12-17
LT2902039T (lt) 2018-06-25
HK1207559A1 (en) 2016-02-05
HK1256639A1 (en) 2019-09-27
HK1101277A1 (en) 2007-10-12
BRPI0513078C1 (pt) 2021-05-25
BRPI0513078B8 (pt) 2019-08-27
HUE038187T2 (hu) 2018-10-29
US20090280131A1 (en) 2009-11-12
FR15C0048I2 (fr) 2015-11-20
CY2015030I1 (el) 2015-11-04
IL180717A0 (en) 2007-06-03
EP2366405B1 (en) 2015-02-25
MY144925A (en) 2011-11-30
LTC1776142I2 (lt) 2022-07-11
SI2902039T1 (en) 2018-07-31
ES2677245T3 (es) 2018-07-31
LU92768I2 (fr) 2015-11-03
AU2005268857B2 (en) 2010-01-28
NO341384B1 (no) 2017-10-30
ECSP077198A (es) 2007-02-28
HRP20181069T1 (hr) 2018-09-07
JP4682200B2 (ja) 2011-05-11
BE2015C041I2 (en:Method) 2024-10-08
NO2015023I1 (no) 2015-11-02
ES2536228T3 (es) 2015-05-21
SI1776142T1 (sl) 2011-11-30
EP2366405A2 (en) 2011-09-21
CY2015030I2 (el) 2017-11-14
RU2426741C2 (ru) 2011-08-20
GB0417487D0 (en) 2004-09-08
WO2006013107A1 (en) 2006-02-09
PT1776142E (pt) 2011-10-06
SI2364729T1 (sl) 2014-08-29
NO2022026I1 (no) 2022-06-24
RU2007108067A (ru) 2008-09-10
AU2005268857B8 (en) 2010-05-27
CN101001645B (zh) 2012-09-05
ZA200700242B (en) 2008-08-27
NO20150065L (no) 2007-03-30
TWI359153B (en) 2012-03-01
US8119131B2 (en) 2012-02-21
HRP20110758T4 (hr) 2015-07-31
US20170355762A1 (en) 2017-12-14
EP2364729B1 (en) 2014-05-14
ATE517924T1 (de) 2011-08-15
BRPI0513078A (pt) 2008-04-22
US20150152178A1 (en) 2015-06-04
US9765140B2 (en) 2017-09-19
TNSN07034A1 (en) 2008-06-02
PT2902039T (pt) 2018-07-17
BR122017009404B1 (pt) 2022-02-22
US20190270804A1 (en) 2019-09-05
NO348010B1 (no) 2024-06-17
EP2902039A1 (en) 2015-08-05
NO337286B1 (no) 2016-02-29
CA2573586C (en) 2013-06-25
US10344084B2 (en) 2019-07-09
SI2366405T1 (sl) 2015-07-31
PL2364729T3 (pl) 2014-10-31
LTPA2018515I1 (lt) 2018-10-25
NO20150064L (no) 2007-03-30
CY1111963T1 (el) 2015-11-04
EP2366405A3 (en) 2012-01-18
HUS1500037I1 (hu) 2017-10-30
PT2366405E (pt) 2015-06-30
AU2005268857C1 (en) 2012-01-19
US20120107325A1 (en) 2012-05-03
NO20070985L (no) 2007-03-30
US20140079719A1 (en) 2014-03-20
CN101001645A (zh) 2007-07-18
DK2366405T3 (en) 2015-05-11
HUS1800040I1 (hu) 2018-11-28
ES2487533T3 (es) 2014-08-21
US20100215666A1 (en) 2010-08-26
BRPI0513078B1 (pt) 2019-02-19
KR20070036166A (ko) 2007-04-02
NL300749I2 (nl) 2017-11-02
PL1776142T3 (pl) 2011-12-30
EP3409288A1 (en) 2018-12-05
CY1116256T1 (el) 2017-02-08
BR122018075556B1 (pt) 2022-10-18
EP2364729A2 (en) 2011-09-14
HUE025815T2 (en) 2016-04-28
CY1115444T1 (el) 2017-01-04
AU2010201689B2 (en) 2011-09-29
EP2364729A3 (en) 2012-01-18
DK1776142T6 (en) 2015-07-06
PL2366405T3 (pl) 2015-08-31
MA28982B1 (fr) 2007-11-01
KR100852523B1 (ko) 2008-08-14
AU2005268857A1 (en) 2006-02-09
LTPA2015029I1 (lt) 2022-07-11
DK1776142T3 (da) 2011-10-31
ES2367440T9 (es) 2021-04-28
PL1776142T4 (pl) 2018-04-30
PL2364729T6 (pl) 2016-06-30
EP1776142B1 (en) 2011-07-27
US8617552B2 (en) 2013-12-31
NO336279B1 (no) 2015-07-06
NZ552658A (en) 2009-11-27
DK2902039T3 (en) 2018-07-16
JP2008507988A (ja) 2008-03-21
IL180717A (en) 2012-07-31
US7807155B2 (en) 2010-10-05
AU2010201689A1 (en) 2010-05-20
EP1776142B3 (en) 2015-06-24
NO20171697A1 (no) 2007-03-30
RU2011113153A (ru) 2012-10-20
PE20060418A1 (es) 2006-06-15
KR100852523B9 (ko) 2025-03-28
AR050200A1 (es) 2006-10-04
PT2364729E (pt) 2014-09-01
CY2018027I1 (el) 2020-05-29
PL2902039T3 (pl) 2018-09-28
MX2007001338A (es) 2008-03-11
NO20151787L (no) 2006-02-06
HRP20110758T1 (en) 2011-11-30
NO2015023I2 (no) 2015-10-26
RU2426741C3 (ru) 2017-11-15

Similar Documents

Publication Publication Date Title
SG155186A1 (en) Il-17 antagonistic antibodies
MY130248A (en) ANTIBODIES TO HUMAN IL-1ß
MY155269A (en) ANTIBODIES TO HUMAN IL-1ß
GEP20115226B (en) P-cadherin antibodies
LUC00025I1 (en:Method)
RS53318B (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
NZ603498A (en) Human cytomegalovirus neutralizing antibodies and use thereof
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
GEP20074222B (en) Antibodies to cd40
EA201000424A1 (ru) Антитела к il-23
NZ600022A (en) Anti CD37 antibodies
EA201070888A1 (ru) Антитела и их производные
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
GEP20104991B (en) Antibodies that bind interleukin-4 receptor
NZ594682A (en) Fully human antibodies specific to cadm1
NZ596381A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
NO20026063D0 (no) Antistoffer mot human MCP-1
EP2192132A3 (en) Anti-IL-20, anti-IL22 and anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EA200700876A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
EP2631248A3 (en) Treatment of tumors using specific anti-L1 antibody
TH114402A (th) แอนติบอดีของ il-17 แอนติโกนิสติก
TH55112B (th) แอนติบอดีของ il-17 แอนติโกนิสติก
UA108734C2 (uk) Моноклональне антитіло, що специфічно зв'язується з протеїнконвертазою субтілізин кексин типу 9 (pcsk9)
NZ603751A (en) Composition for treating disease